Context Therapeutics Inc. (CNTX) company profile
Close on Nov 16, 2026Market cap $15.24MP/E –Yield –
About Context Therapeutics
Pharmaceutical Preparations, SIC 2834
Context Therapeutics is a clinical-stage biopharmaceutical company that advances T cell engaging bispecific antibody therapeutics for the treatment of solid tumors. Its drug development pipeline targets patient populations with unmet oncology needs, including gynecologic, testicular, bladder, lung, colon, and breast cancers. The company's lead investigational drug candidates include CTIM-76, CT-95, and CT-202, which direct immune responses against specific tumor-associated antigens such as Claudin 6, Mesothelin, and Nectin-4. Because Context Therapeutics remains in clinical development, it has not brought commercial products to market.
The company operates without internal manufacturing, sales, or commercial product distribution facilities, choosing to outsource research, drug product manufacturing, and diagnostic preparation to external contract partners. It pursues clinical trials and global patent protection across multiple jurisdictions, including the United States, Europe, Canada, Australia, and parts of Asia, while retaining worldwide development and commercialization rights to its core programs. Context Therapeutics does not identify specific physical headquarters locations or facility counts in the provided text.
Summary of the business section of Context Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Context Therapeutics Inc.
- Founded
- 2021
- Headquarters
- Philadelphia, PA
- Address
- 2001 Market Street, Suite 3915 Unit #15 19103
- Phone
- (267) 225-7416
- Website
- contexttherapeutics.com
- Employees
- 15, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- CohnReznick LLP, Parsippany, New Jersey
Stock & identifiers
- Ticker
- CNTX
- Exchange
- Nasdaq
- IPO date
- Oct 20, 2021
- Shares outstanding
- 92M, Aug 3, 2026
- Public float
- $57.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1842952
- CUSIP
- 21077P108
- ISIN
- US21077P1084
- FIGI
- BBG011YW6H86
- Share class FIGI
- BBG011YW6J46
- LEI
- 549300U5ISIWCBXD6W77
- EIN
- 86-3738787
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Martin A. Lehr | Chief Executive Officer, Director | 1,079,891 |
| Alex C. Levit | Chief Legal Officer, Corp. Sec | 81,983 |
| Jennifer Lynn Minai-Azary | Chief Financial Officer | 80,010 |
| Karen Deborah Chagin | Chief Medical Officer | – |
| Ullmann Claudio Dansky | Chief Medical Officer | – |
| Andy Pasternak | Director | – |
| Linda West | Director | – |
| Karen L. Smith | Director | – |
| Jennifer Evans Stacey | Director | – |
| Philip W. Kantoff | Director | 3,533 |
| Luke Nathaniel Walker | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Martin Lehr Chief Executive Officer | $588.52K | $15.00K | $551.42K | $300.00K | $10.50K | $1.47M | +45% |
| Alex Levit Chief Legal Officer and Corporate Secretary | $397.81K | $8.00K | $240.36K | $160.00K | $10.50K | $816.67K | +22% |
| Jennifer Minai-Azary Chief Financial Officer and Treasurer | $421.73K | $8.50K | $255.41K | $170.00K | $10.50K | $866.14K | +24% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Oct 20, 2021
- Offer price
- $5.00
- Securities offered
- 5,000,000
- Gross proceeds
- $25.00M
- Exchange
- Nasdaq
- First trading day
- Oct 20, 2021
- First-day close
- $5.10+2.0%
- Lock-up ends (est.)
- Apr 18, 2022
“Per Share Total Initial public offering price $ 5.00 $ 25,000,000 Underwriting discounts and commissions (1) $ 0.375 $ 1,875,000 Proceeds, before expenses, to us $ 4.625 $ 23,125,000 (1) In addition, we have agreed to reimburse the underwriter for certain expenses.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 1, 2026, we had fifteen full-time employees and no part-time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 31, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 2, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 28, 2025 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 27, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Oct 20, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 23, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 3, 2021 | Name change | Name changed from Context Therapeutics LLC to Context Therapeutics Inc. |
See a number that looks wrong?